HCPLive

CDC Warns of New Strain of Virus Responsible for Most Cases of Gastroenteritis

 
THURSDAY, Jan. 24 (HealthDay News) -- A novel strain of norovirus, GII.4 Sydney, which was first detected in Australia in March of last year, was responsible for the majority of norovirus outbreaks in the United States from September through December 2012, according to a report published in the Jan. 25 issue of the U.S. Centers for Disease Control and Prevention's Morbidity & Mortality Weekly Report.

Leslie Barclay, from the CDC in Atlanta, and colleagues analyzed 2012 CaliciNet data on norovirus activity to determine the prevalence of GII.4 Sydney-associated outbreaks in the United States.

The researchers noted 266 reported outbreaks of norovirus, which is highly contagious and causes acute gastroenteritis, leading to nausea and vomiting. Of these cases, 141 (53 percent) were caused by the new strain.

"GII.4 noroviruses remain the predominant cause of norovirus outbreaks, and the GII.4 Sydney strain appears to have replaced the previously predominant strain, GII.4 New Orleans. Compared with other norovirus genotypes, GII.4 noroviruses have been associated with increased rates of hospitalizations and deaths during outbreaks," the authors write. "Health care providers and public health practitioners should remain vigilant to the potential for increased norovirus activity in the ongoing season related to the emergent GII.4 Sydney strain."
 

Full Text


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the US Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.
Treating patients with migraines and psychiatric comorbidities can require a delicate balancing act of medications and other forms of therapy.
In many cases helping patients manage their migraine headaches can prove to be enough of a challenge. Adding psychiatric conditions to the diagnosis can further complicate the treatment process for doctors.
Patients with exocrine pancreatic insufficiency treated with pancreatin for up to one year experienced improvements in gastrointestinal symptoms and reduction in the severity of their recurrent pain.
$vAR$